CMMBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Chemomab Therapeutics Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 23, 2026
$1.17−0.09 (-7.51%)
Close on Oct 19, 2026
- Market cap
- $749.09M
- P/E (TTM)
- 65.0
- Dividend yield
- –
Share price
−$2.15 (−64.76%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $749.09M
- P/E ratio
- 65.0
- Price to sales
- –
- Price to book
- 86.25
- Dividend yield
- –
- Free cash flow yield
- -1.49%
Fundamentals
- Net income
- -$9.00M
- EPS, diluted
- $0.02
- Free cash flow
- -$11.13M
- Book value per share
- $0.01
- Diluted shares
- 640M
Eleven years at a glance
Fiscal years 2015 to 2025, USD
Operating income
-$112.00M
Net income
-$9.00M
EPS, diluted
$0.02-53.8% YoY
Free cash flow
-$11.13M
Reported period